Shilpa Medicare Ltd Q3 FY26 Earnings Analysis
Published 22 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹14.1K Cr
Price
₹815
Market Cap
₹14.1K Cr
P/E Ratio
49.6
How does Shilpa Medicare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Shilpa Medicare Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Shilpa Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹437 Cr, net profit ₹108 Cr.
Full financials →Earnings Summary
FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
📊 Revenue & Sales Performance
- →FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth.
- →Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income.
- →Launches like NorUDCA and transdermal Rotigotine to boost revenues.
- →Biologics and Formulation segments anticipated to drive higher growth; API segment to grow steadily.
- →Increased utilization and new oral solid line at formulation plant to support revenue ramp-up.
- →Oncology business expected to grow with resolved product validations and increased capacity.
- →CDMO peptide facility launching with ~INR40 crore capex, expecting inquiries and scale-up.
- →Licensing income stable at ~INR150 crores annually, with quarter-to-quarter variations normal.
- →Albumin product commercialization anticipated in India by FY '28, adding new revenue streams.
- →Capacity expansions and productivity improvements planned to increase asset turnover and output.
📈 Profitability & Margins
- →Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
- →EBITDA grew by 41% YoY to INR115 crores in Q3; margins improved from 26% to 28%.
- →PAT for 9 months nearly doubled compared to FY '25 full year, indicating strong profit acceleration.
- →ROCE significantly improved from 3.5% in FY '23 to over 17% in first 9 months FY '26, expected to increase further with scaling.
- →Formulation business ex-licensing revenue grew 104% QoQ and 83% YoY for 9 months, indicating strong core earnings growth.
- →Expected growth drivers for FY '27 & FY '28: Biologics and Formulation segments; API expected to grow steadily.
- →Q4 FY '26 and FY '27 expected to see meaningful revenue ramp-ups, particularly from NorUDCA and oncology product validations.
- →Licensing income stable (~INR150 crores/year), with manufacturing revenue expected from orphan drug partners.
🏗️ Capital Expenditure Plans
- →New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
- →Investment in a new oral solid formulation line recently commissioned to support upcoming launches and generate additional revenues in FY '27 (Page 15).
- →Significant past capex completed; current focus is on execution, scaling, and maximizing ROCE from existing investments (Page 6).
- →Capex of about INR 87 crores incurred during Q3 FY '26, with expectation to mainly fund capex through internal accruals (Page 6).
- →No long-gestating investments planned; peptide investment is strategic with focus on timely patent expiries (Page 13).
- →Incremental capex aimed at increasing production efficiency, capacity utilization, and supporting ongoing product development (Pages 15-16).
💰 Fundraising & Capital Structure
- →As of the latest update, Shilpa Medicare Limited's net debt was about INR 625 crores as of December 31.
- →The company is not planning to increase borrowing and is focused on managing debt levels prudently.
- →They continue repaying term loans, so the overall debt is expected to reduce gradually.
- →However, the company might take additional borrowing occasionally based on business opportunities or requirements but intends to keep debt within manageable limits.
- →Funding for ongoing and future capex programs is expected to be mainly through internal accruals.
- →No explicit mention of planned equity fundraising in the discussion.
- →Overall, the approach is cautious towards debt, aiming to balance growth investments and debt reduction steadily.
📋 Order Book & Pipeline
- →NorUDCA launch has been very successful, exceeding expectations with a strong order book as of Q3 FY26.
- →Good traction in NorUDCA is noted with an expanding order book from the three marketing partners.
- →For oncology and other products, specific order book numbers were not disclosed due to confidentiality.
- →Formulation segment shows stable base revenue, with Europe at ~INR73 crores indicating a steady order flow.
- →The company expects increased ramp-up and order inflow from new product launches and capacity expansions in FY27.
- →Partnerships for ADC biosimilars and other product pipelines are expected to contribute to future order books starting FY27.
Key Metrics
Frequently Asked Questions
What were Shilpa Medicare Ltd Q3 FY26 results?
FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
What is Shilpa Medicare Ltd share price analysis?
Shilpa Medicare Ltd currently shows a neutral. The stock trades at a P/E of 49.6 with a market cap of ₹14,116 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare Ltd planning capital expenditure?
New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
Keep Shilpa Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.